Colorectal Cancer - Eight-Market Drug Forecast and Market Analysis

1.1 The colorectal cancer market will grow to $21.8B by 2031, at a compound annual growth rate of 3.3%
1.2 Combination therapies and immunotherapies for distinct segments are key R&D strategies in CRC
1.3 The level of unmet clinical need in colorectal cancer remains high during the forecast period, despite dramatic improvements by historical standards
1.4 The colorectal cancer pipeline is robust, with plenty of room for new market entrants
1.5 What do physicians think?

2.1 Catalyst
2.2 Related reports
2.3 Upcoming reports

3.1 Etiology and pathophysiology
3.1.1 Etiology
3.1.2 Pathophysiology
3.1.3 Classification and staging systems

4.1 Disease background
4.2 Risk factors and comorbidities
4.3 Global and historical trends
4.4 Forecast methodology
4.4.1 Sources
4.4.2 Forecast assumptions and methods
4.4.3 Forecast assumptions and methods: diagnosed incident cases of CRC
4.4.4 Forecast assumptions and methods: diagnosed incident cases of CRC by AJCC stage at diagnosis
4.4.5 Forecast assumptions and methods: diagnosed incident cases of CRC by recurrence of stages I-III into stage IV disease
4.4.6 Forecast assumptions and methods: diagnosed incident cases of CRC by molecular markers
4.4.7 Forecast assumptions and methods: five-year diagnosed prevalent cases of CRC
4.5 Epidemiological forecast for CRC (2021-31)
4.5.1 Diagnosed incident cases of CRC
4.5.2 Age-specific diagnosed incident cases of CRC
4.5.3 Sex-specific diagnosed incident cases of CRC
4.5.4 Diagnosed incident cases of CRC by AJCC stage at diagnosis
4.5.5 Diagnosed incident cases of CRC by recurrence of stages I-III into

• stage IV disease

4.5.6 Diagnosed incident cases of CRC by molecular markers
4.5.7 Five-year diagnosed prevalent cases of CRC
4.6 Discussion
4.6.1 Epidemiological forecast insight
4.6.2 COVID-19 impact
4.6.3 Limitations of the analysis
4.6.4 Strengths of the analysis

5.1 Diagnosis and Treatment Overview
5.2 KOL insights on disease management
5.2.1 US-specific KOL insights on disease management
5.2.2 5EU-specific KOL insights on disease management
5.2.3 Japan-specific KOL insights on disease management
5.2.4 China-specific KOL insights on disease management

6.1 Overview

7.1 Overview
7.2 Improving treatments for patients with KRAS/NRAS mutations
7.3 Improving treatment options in precision medicine
7.4 Overcoming resistance to EGFR- and VEGF-targeted therapies
7.5 Reduced age for routine disease screening

8.1 Overview of R&D strategies
8.1.1 Targeting MSS patients with immunotherapy
8.1.2 Combination Therapies
8.2 Clinical trials design
8.2.1 Increasing adoption of secondary quality of life endpoints
8.2.2 Increasing adoption of surrogate endpoints

9.1 Overview
9.2 Promising drugs in clinical development

10.1 Overview
10.2 Competitive assessment

11.1 Overview
11.2 Deal-making trends

12.1 Global Markets
12.1.1 Forecast
12.1.2 Drivers and barriers - global issues
12.2 US
12.2.1 Forecast
12.2.2 Key events
12.2.3 Drivers and barriers
12.3 5EU
12.3.1 Forecast
12.3.2 Key events
12.3.3 Drivers and barriers
12.4 Japan
12.4.1 Forecast
12.4.2 Key events
12.4.3 Drivers and barriers
12.5 China
12.5.1 Forecast
12.5.2 Key events
12.5.3 Drivers and barriers

13.1 Bibliography
13.2 Abbreviations
13.3 Methodology
13.3.1 Forecasting methodology
13.4 Primary research - KOLs interviewed for this report
13.4.1 KOLs
13.5 Primary research - prescriber survey
13.6 About the authors
13.6.1 Analysts
13.6.2 Therapy Area Director
13.6.3 Epidemiologist
13.6.4 Epidemiology reviewers
13.6.5 Vice President of Disease Intelligence and Epidemiology"

Table 1: Colorectal cancer: key metrics in the 8MM
Table 2: 8MM, TNM staging and classification for CRC
Table 3: 8MM, Diagnosed incident cases of CRC by molecular markers, both sexes, ages =18 years, N, 2021
Table 4: CRC screening practices across the 8MM
Table 5: Treatment guidelines for CRC across the 8MM
Table 6: Current landscape of approved CRC agents in the 8MM
Table 7: Comparison of published clinical data for late-stage pipeline agents in CRC
Table 8: Top 10 completed deals by value, 2021-2023
Table 9: CRC market - global drivers and barriers, 2021-2031
Table 10: Key events impacting sales for CRC in the US, 2021-2031
Table 11: CRC market - drivers and barriers in the US, 2021-2031
Table 12: Key events impacting sales for CRC in the 5EU, 2021-2031
Table 13: CRC market - drivers and barriers in the 5EU, 2021-2031
Table 14: Key events impacting sales for CRC in Japan, 2021-2031
Table 15: CRC market - drivers and barriers in Japan, 2021-2031
Table 16: Key events impacting sales for CRC in China, 2021-2031
Table 17: CRC market - drivers and barriers in China, 2021-2031
Table 18: High-prescribing physicians (non-KOLs) surveyed, by country

Figure 1: Global sales forecast by country for CRC in 2021 and 2031
Figure 2: Analysis of the company portfolio gap in CRC during the forecast period
Figure 3: Competitive assessment of the marketed and pipeline drugs benchmarked against Braftovi, targeted therapy agents
Figure 4: Competitive assessment of the marketed and pipeline drugs benchmarked against Keytruda, immunotherapy agents
Figure 5: Risk factors associated with CRC
Figure 6: Tumor sites of the colon and rectum
Figure 7: 8MM, Diagnosed incidence of CRC, men, cases per 100,000 population, ages =18 years, 2011-31
Figure 8: 8MM, Diagnosed incidence of CRC, women, cases per 100,000 population, ages =18 years, 2011-31
Figure 9: 8MM, sources used and not used to forecast the diagnosed incident cases of CRC
Figure 10: 8MM, sources used to forecast the diagnosed incident cases of CRC by stage at diagnosis
Figure 11: 8MM, sources used to forecast the diagnosed incident cases of CRC by recurrence into stage IV disease
Figure 12: 8MM, sources used to forecast the diagnosed incident cases of CRC by molecular markers (KRAS mutation, NRAS mutation, BRAF mutation, BRAF V600E mutation, and PIK3CA/PTEN mutation)
Figure 13: 8MM, sources used to forecast the diagnosed incident cases of CRC by molecular markers (MSI-H/dMMR molecular subtype, HER2 amplification, MET amplification, and NTRK gene fusion)
Figure 14: 8MM, sources used to forecast the diagnosed incident cases of CRC by molecular markers (DPYD, high TMB, elevated CEA, and UGT1A1 mutation)
Figure 15: 8MM, sources used to forecast the diagnosed incident cases of CRC by molecular markers (POLE mutation, TP53 mutation, APC mutation, and PD-L1 expression on tumors)
Figure 16: 8MM, Sources used to forecast the five-year diagnosed prevalent cases of CRC
Figure 17: 8MM, Diagnosed incident cases of CRC, N, both sexes, ages =18 years, 2021
Figure 18: 8MM, Diagnosed incident cases of CRC by age, N, both sexes, 2021
Figure 19: 8MM, Diagnosed incident cases of CRC by sex, N, all ages, 2021
Figure 20: 8MM, Diagnosed incident cases of CRC by AJCC stage at diagnosis, N, all ages, 2021
Figure 21: 8MM, diagnosed incident cases of CRC by recurrence of stages I-III into stage IV disease, N, both sexes, ages =18 years, 2021
Figure 22: 8MM, Five-year diagnosed prevalent cases of CRC, N, both sexes, ages =18 years, 2021
Figure 23: Treatment algorithm for localized CRC
Figure 24: Treatment algorithm for advanced/metastatic CRC
Figure 25: Unmet needs and opportunities in CRC
Figure 26: Overview of the ex-China development pipeline in CRC (Phase II-Phase III)
Figure 27: Key late-stage trials for targeted therapy CRC candidates that the Publisher expects to be approved in the 8MM during the forecast period
Figure 28: Key late-stage trials for immunotherapy CRC candidates that the Publisher expects to be approved in the 8MM during the forecast period
Figure 29: Competitive assessment of the marketed and pipeline drugs benchmarked against Braftovi, targeted therapy agents
Figure 30: Competitive assessment of the marketed and pipeline drugs benchmarked against Keytruda, immunotherapy agents
Figure 31: Analysis of the company portfolio gap in CRC during the forecast period
Figure 32: Global (8MM) sales forecast by country for CRC in 2021 and 2031
Figure 33: Sales forecast by class for CRC in the US in 2021 and 2031
Figure 34: Sales forecast by class for CRC in the 5EU in 2021 and 2031
Figure 35: Sales forecast by class for CRC in Japan in 2021 and 2031
Figure 36: Sales forecast by class for CRC in China in 2021 and 2033